Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 15, Issue 5, 1995, Pages 571-582

  Palinski, Wulf ^a   Koschinsky, Theodor ^b   Butler, Susan W ^a   Miller, Elizabeth ^a   Vlassara, Helen ^c   Cerami, Anthony ^c   Witztum, Joseph L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c PICOWER INST FOR MEDICAL RESEARCH   (United States)

Author keywords

advanced glycosylation end products; arteriosclerosis; autoantibodies; immunocytochemistry; oxidation

Indexed keywords

AUTOANTIBODY; FATTY ACID; HEXANOIC ACID; LOW DENSITY LIPOPROTEIN RECEPTOR;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; ATHEROSCLEROSIS; AUTOIMMUNITY; CLINICAL ARTICLE; DIABETES MELLITUS; FEMALE; HUMAN; IMMUNOCYTOCHEMISTRY; LIPID PEROXIDATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN GLYCOSYLATION; RABBIT;

EID: 0029066992     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.15.5.571     Document Type: Article

References (72)

1. Pyörälä K, Laakso M, Uusitupa M. Diabetes and arteriosclerosis: an epidemiologic view. Diabetes Metab Rev. 1987;3:463-524.
2. Brownlee M. Glycation and diabetic complications. Diabetes. 1994;43:836-841.
3. Cerami A, Vlassara H, Brownlee M. Role of advanced glycosylation products in complications of diabetes. Diabetes Care. 1988;11:73-79.
4. Njoroge FG, Monnier VM. The chemistry of the Maillard reaction under physiological conditions - a review. Prog Clin Biol Res. 1989;304:85-107.
5. Monnier VM. Nonenzymatic glycosylation, the Maillard reaction and the aging process. J Gerontol (Biol Sci). 1990;45:B105-B111.
6. Baynes JW, Watkins NG, Fisher CI, Hull CJ, Patrick JS, Ahmed MU, Dunn JA, Thorpe SR. The Amadori product on protein: structure and reactions. Prog Clin Biol Res. 1989;304:43-67.
7. Kato H, Hayase F, Dong BS, Oimomi M, Baba S. 3-Deoxyglucosone, an intermediate product of the Maillard reaction. Prog Clin Biol Res. 1989;304:69-84.
8. Witztum JL, Mahoney EM, Branks MJ, Fisher M, Elam R, Steinberg D. Nonenzymatic glucosylation of low-density lipoprotein alters its biological activity. Diabetes. 1982;31:283-291.
9. Curtiss LK, Witztum JL. Plasma apolipoproteins A-I, A-II, B, C-I and E are glucosylated in hyperglycemic diabetes. Diabetes. 1985; 34:452-461.
10. Steinbrecher UP, Witztum JL. Glucosylation of low density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism. Diabetes. 1984;33:130-134.
11. Witztum JL, Koschinsky T. Metabolic and immunological consequences of glycation of low density lipoproteins. In: Baynes JW, Monnier VM, eds. The Maillard Reaction in Aging, Diabetes and Nutrition. New York, NY: Alan R Liss Inc; 1989:219-234.
12. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci U S A. 1993;90:6434-6438.
13. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest. 1991;87: 432-438.
14. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation products of collagen covalently trap low-density lipoprotein. Diabetes. 1985;34:938-941.
15. Brownlee M, Pongor S, Cerami A. Covalent attachment of soluble proteins by nonenzymatically glycosylated collagen: role of the in situ formation of immune complexes. J Exp Med. 1983;158: 1739-1744.
16. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915-924.
17. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991;88:1785-1792.
18. Palinski W. Lipoprotein oxidation: mechanisms and implications for atherogenesis. In: Born GVR, Schwartz CD, eds. New Horizons in Coronary Heart Disease. London, England: Current Science; 1993:13.1-13.11.
19. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A. 1979;76:333-337.
20. Vlassara H, Brownlee M, Cerami A. High-affinity receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. Proc Natl Acad Sci U S A. 1985;82:5588-5592.
21. Takata K, Horiuchi S, Araki N, Shiga M, Saitoh M, Morino Y. Endocytic uptake of nonenzymatically glycosylated proteins is mediated by a scavenger receptor for aldehyde-modified proteins. J Biol Chem. 1988;263:14819-14825.
22. Radoff S, Cerami A, Vlassara H. Isolation of surface binding protein specific for advanced glycosylation end products from mouse macrophage-derived cell line RAW 264.7. Diabetes. 1990;39:1510-1518.
23. Neeper M, Schmid AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. 1992;267:14988-15004.
24. Schmidt AM, Mora R, Cao R, Yan SD, Brett J, Ramakrishnan R, Tsang TC, Simionescu M, Stern D. The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide. J Biol Chem. 1994;269:9882-9888.
25. Kirstein M, Brett J, Radoff S, Ogawa S, Stern D, Vlassara H. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc Natl Acad Sci U S A. 1990;87:9010-9014.
26. Schmidt AM, Yan SD, Brett J, Mora R, Nowygrod R, Stern D. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest. 1993;91:2155-2168.
27. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci U S A. 1987;84:2995-2998.
28. Yan SD, Schmid AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem. 1994;269:9889-9897.
29. Dunn JA, Patrick JS, Thorpe SR, Baynes JW. Oxidation of glycated proteins: age-dependent accumulation of N-epsilon-(carboxymethyl) lysine in lens protein. Biochemistry. 1989;28:9464-9468.
30. Wolff SP, Bascal ZA, Hunt JV. "Autooxidative glycosylation": free radicals and glycation theory. In: Baynes JW, Monnier VM, eds. The Maillard Reaction in Aging, Diabetes and Nutrition. New York, NY: Alan R Liss Inc; 1989:259-278.
31. Mullarkey CJ, Edelstein D, Brownlee M. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun. 1990;173: 932-939.
32. Hicks M, Delbridge L, Yue, DK, Reeve TS. Catalysis of lipid peroxidation by glucose and glycosylated collagen. Biochem Biophys Res Commun. 1988;151:649-655.
33. Hicks M, Delbridge L, Yue, DK, Reeve TS. Increase in crosslinking of nonenzymatically glycosylated collagen induced by products of lipid peroxidation. Arch Biochem Biophys. 1989;268:249-254.
34. Hunt JV, Smith CCT, Wolff SP. Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes. 1990;39:1420-1424.
35. Hunt JV, Bottoms MA, Clare K, Skamarauskas JT, Mitchinson MJ. Glucose oxidation and low-density lipoprotein-induced macrophage ceroid accumulation: possible implications for diabetic atherosclerosis. Biochem J. 1994;300:243-249.
36. Nishigaki I, Hagihara M, Tsunekawa H, Maseki M, Yagi K. Lipid peroxide levels of serum lipoprotein fractions of diabetic patients. Biochem Med. 1981;25:373-378.
37. Morel DW, Chisolm GM. Antioxidant treatment of diabetic rats inhibits lipoprotein oxidation and cytotoxicity. J Lipid Res. 1989;30: 1827-1834.
38. Nakamura Y, Horii Y, Nishino T, Shiiki H, Sakaguchi Y, Kagoshima T, Dohi K, Makita Z, Vlassara H, Bucala R. Immunocytochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol. 1993;143:1649-1656.
39. Haberland ME, Fong D, Cheng L. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science. 1988;241:215-218.
40. Palinski W, Rosenfeld ME, Ylä-Herttuala S, Gurtner GC, Socher SA, Butler S, Parthasarathy S, Carew TE, Steinberg D, Witztum JL. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A. 1989;86:1372-1376.
41. Boyd HC, Gown AM, Wolfbauer G, Chait A. Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe Heritable Hyperlipidemic rabbit. Am J Pathol. 1989;135:815-826.
42. Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84:1086-1095.
43. Palinski W, Ylä-Herttuala S, Rosenfeld ME, Butler S, Socher SA, Parthasarathy S, Curtiss LK, Witztum JL. Antisera and monoclonal antibodies specific for epitopes generated during the oxidative modification of low density lipoprotein. Arteriosclerosis. 1990;10: 325-335.
44. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193: 1831-1841.
45. Gendloff EH, Casale WL, Ram BP, Tai JH, Pestka JJ, Hart LP. Hapten-protein conjugates prepared by the mixed anhydride method: cross-reactive antibodies in heterologous antisera. J Immunol Methods. 1986;92:15-20.
46. Steinbrecher UP, Fisher M, Witztum JL, Curtiss LK. Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation or carbamylation: generation of antibodies specific for derivatyzed lysine. J Lipid Res. 1984;25:1109-1116.
47. Horiuchi S, Shiga M, Araki N, Takata K, Saitoh M, Morino Y. Evidence against in vivo presence of 2-(2-furoyl)-4(5)-(2furanyl)-1H-imidazole, a major fluorescent advanced end product generated by nonenzymatic glycosylation. J Biol Chem. 1988;263:18821-18826.
48. Rosenfeld ME, Palinski W, Ylä-Herttuala S, Butler S, Witztum JL. Distribution of oxidation-specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis. 1990;10:336-349.
49. Palinski W, Ord V, Plump AS, Breslow JL, Steinberg D, Witztum JL. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis: demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb. 1994;14:605-616.
50. Young SG, Witztum JL, Casal DC, Curtiss LK, Bernstein S. Conservation of the low density lipoprotein receptor-binding domain of apoprotein B: demonstration by a new monoclonal antibody, MB-47. Arteriosclerosis. 1986;6:178-188.
51. Tsukada T, Rosenfeld ME, Ross R, Gown AM. Immunocytochemical analysis of cellular components of lesions of atherosclerosis in Watanabe and fat-fed rabbits using monoclonal antibodies. Arteriosclerosis. 1986;6:601-613.
52. Witztum JL, Steinbrecher UP, Fisher M, Kesaniemi A. Nonenzymatic glucosylation of homologous LDL and albumin render them immunogenic in the guinea pig. Proc Natl Acad Sci U S A. 1983;80:2757-2761.
53. Pongor S, Ulrich PC, Bencsath FA, Cerami A. Aging of proteins: isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose. Proc Natl Acad Sci U S A. 1984;81:2684-2688.
54. Njoroge FG, Fernandes AA, Monnier VM. Mechanism of formation of the putative advanced glycosylation end product and protein cross-link 2-(2-furoyl)-4(5)-(2-furanyl)-1H-imidazole. J Biol Chem. 1988;263:10646-10652.
55. Chang JCF, Ulrich PC, Bucala R, Cerami A. Detection of an advanced glycosylation product bound to protein in situ. J Biol Chem. 1985;260:7970-7974.
56. Gerhardinger C, Lapolla A, Crepaldi G, Fedele D, Ghezzo E, Seraglia R, Traldi P. Evidence of acid hydrolysis as responsible for 2-(2 furoyl)-4(5)-(2 furanyl)-1H-imidazole (FFI) production. Clin Chim Acta. 1990;189:335-340.
57. Lapolla A, Gerhardinger C, Ghezzo E, Seraglia R, Sturaro A, Crepaldi G, Fedele D, Traldi P. Identification of furoyl-containing advanced glycation products in collagen samples from diabetic and healthy rats. Biochim Biophys Acta. 1990;1033:13-18.
58. Makita Z, Vlassara H, Cerami A, Bucala R. Immunocytochemical detection of advanced glycosylation end products in vivo. J Biol Chem. 1992;267:5133-5138.
59. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med. 1991;325:836-842.
60. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci U S A. 1991;88: 11555-11558.
61. Sell DR, Monnier VM. Structure elucidation of a senescence cross-link from human extracellular matrix. J Biol Chem. 1989; 264:21597-21602.
62. Hayase F, Nagaraj RH, Miyata S, Njoroge FG, Monnier VM. Aging of proteins: immunological detection of a glucose-derived pyrrole formed during Maillard reaction in vivo. J Biol Chem. 1989;263: 3758-3764.
63. Monnier VM, Sell DR, Abdul-Karim FW, Emancipator SN. Collagen browning and cross-linking are increased in chronic experimental hyperglycemia. Diabetes. 1988;37:867-872.
64. Sell DR, Monnier VM. End-stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen. J Clin Invest. 1990;85:380-384.
65. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991;40:405-412.
66. Lyons TJ. Glycation and oxidation: a role in the pathogenesis of atherosclerosis. Am J Cardiol. 1993;71:26B-31B.
67. Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A, Vlassara H. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci U S A. 1994;91: 9441-9445.
68. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 1993;91:2546-2551.
69. Witztum JL, Steinbrecher UP, Kesaniemi YA, Fisher M. Autoantibodies to glucosylated proteins in the plasma of patients with diabetes mellitus. Proc Natl Acad Sci U S A. 1984;81:3204-3208.
70. Ylä-Herttuala S, Palinski W, Butler S, Picard S, Steinberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized low density lipoprotein. Arterioscler Thromb. 1994;14:32-40.
71. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest. 1991;64:5-15.
72. Palinski W, Miller E, Witztum JL. Immunization of LDL receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci U S A. 1995;92:821-825.